Improvement in the results of treatment of osteogenic sarcoma.
Experience with 70 patients having osteogenic sarcomas treated between 1968 and 1973 demonstrated the importance of persistence in the management of the disease of these patients. Resection for pulmonary metastases in one or both lungs, often on more than one occasion, will salvage a number of these patients, thus improving the cure rate. Adriamycin has proved an effective palliative agent and a useful adjuvant to surgical therapy. Although the cure rate of tumors arising distal to the knee is much higher than that of more proximally situated tumors, resection of osteogenic sarcomas of the distal part of the femur does not require removal of the entire femur when care is taken to resect well above the site of the apparent tumor. Some osteogenic sarcomas are sensitive to adequate dosages of radiation therapy, but the exact role of this method is yet to be determined. No definite beneficial result could be attributed to any of a variety of modalities of immune stimulation therapy.
D000293:Adolescent; D000328:Adult; D000367:Age Factors; D000368:Aged; D000671:Amputation, Surgical; D001859:Bone Neoplasms / Q000188:drug therapy / Q000601:surgery*; D002648:Child; D004317:Doxorubicin / Q000627:therapeutic use; D006428:Hemipelvectomy; D006801:Humans; D007866:Leg / Q000601:surgery; D008175:Lung Neoplasms / Q000601:surgery; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D009362:Neoplasm Metastasis; D012516:Osteosarcoma / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery*; D010166:Palliative Care; D011013:Pneumonectomy; D012075:Remission, Spontaneous
D004317:Doxorubicin; D008727:Methotrexate